Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > AACR 2024 : Cancer vaccines get reintroduction with pathway

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Apr 11, 2024 9:16pm

112 Views

Post# 35984657

RE:AACR 2024 : Cancer vaccines get reintroduction with pathway

April 10, 2024 - A session at the American Association for Cancer Research (AACR) annual meeting posed a key question: Are cancer vaccines ready for prime time?

If you ask Scott Kopetz, M.D., Ph.D., of the University of Texas MD Anderson Cancer Center, the answer is a quick yes.

Much of the focus at AACR was on pancreatic cancer

<< Previous

Bullboard Posts

Next >>

These cold weather stocks are looking to heat up for winter